Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, 08025, Spain
NCT Number: NCT01306370
Objectives:
a) Principal: To assess if the fibrin glue or the tranexamic acid reduce less than 20% the blood losses with respect to the habitual haemostasia in patients with arthroplasty total of knee.
Secondaries: To assess the treatment safety. To perform a cost- analyses.
Methods: Randomized, unicentric, and parallel clinical trial with four comparative groups: Tissucol® (fibrin glue), fibrin glue manufactured by the Cryoseal® system (Banc de Sang i Teixits de Catalunya), tranexamic acid and habitual haemostasia.
Nº of participant centres: 1. Random allocation will be centralised.
Main outcome: Blood losses (ml) in the post-operatory period collected by the habitual drain system.
Secondary outcomes: Proportion of patients with blood transfusion, complications of surgery wound, pre and post-operative haemoglobin, units of blood transfused, post-operative mortality, days of hospital stay, safety of interventions assessed.
Size sample calculation: The number needed of patients is 172 (43 per group) to demonstrate a 20% difference in the post-operative blood losses between the treatments assessed and the habitual haemostasia, with a statistical power of 80% and a 0.05 bilateral alpha, and a 20% of withdrawals.
Statistical analysis: The investigators will perform a comparison of outcomes through the "t" test, the Mann-Whitney test of chi square, depending of the evaluated outcomes, quantitative or ordinals or qualitative, respectively. The software used will be Statistical Package for the Social Sciences (SPSS) version 17.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Barcelona, Catalonia, 08025, Spain
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.
Each dosage: 2 ampoules of 500mg/5 mL/ampoule
Other names: Amchafibrin
Topical administration, before to close the surgical wound. Dosage: 2 mL.
Other names: Tissucol
Topical administration, before to close the surgical wound.
The surgical habitual haemostasis.
Time frame: During the first 48h after the surgical intervention
Blood loss (mL) by the surgical wound collected by drain systems.
Time frame: During the first postoperative week
Time frame: During the first postoperative month
Time frame: During the first postoperative month
Time frame: During the first postoperative month
Time frame: During the first postoperative week
Time frame: During the first postoperative week
Time frame: During the first postoperative week
Time frame: Days
Time frame: During the first postoperative month
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Other
Prevention of Postoperative Blood Loss: Randomised Unicentric Parallel Clinical Trial That Assess the Efficacy of Fibrin Glue and Tranexamic Acid in Surgical Patients With a Total Knee Arthroplasty.
Acronym: ATRHEMOS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06203483
Arthritis, Joint Diseases
Bursa, Turkey (Türkiye)
View Trial DetailsNCT07398742
Body Weight, Juvenile polyposis syndrome
Copenhagen NV, Denmark
View Trial DetailsNCT04598568
Knee Arthropathy
View Trial DetailsNCT06084403
Arthritis, Joint Diseases
Bursa, Turkey (Türkiye)
View Trial Details